Amendments to the Claims

Please amend the claims as follows, and please add claims 24-32. The following list of claims is complete and supercedes all prior lists of claims.

- 1. (Currently amended) <u>In a A carrier</u> solution for the introduction and washout of vitrifiable concentrations of cryoprotectants in a cell, tissue or organ, <u>the improvement</u> comprising <u>inclusion of bicarbonate</u> mannitol and lactose <u>in the solution</u>.
- 2. (Previously presented) The solution of Claim 1 further comprising vitrifiable concentrations of cryoprotectant.
- 3. (Previously presented) The solution of Claim 2 wherein said cryoprotectant comprises dimethyl sulfoxide, formamide, and ethylene glycol.
- 4. (Previously presented) The solution of Claim 2, wherein said cryoprotectant comprises polyvinyl alcohol or a copolymer of vinyl alcohol and vinyl acetate.
 - 5. (Cancelled)
- 6. (Previously presented) The solution of Claim 2, wherein said cryoprotectant comprises polyglycerol.

2

7. (Currently amended) The solution of Claim 2 wherein said solution comprises impermeants selected from the group consisting of: polyglycerol, polyvinylpyrrolidone, polyvinyl alcohol, a copolymer of vinyl alcohol and vinyl acetate, and sucrose;

and wherein said solution has a tonicity of 1.2 to $\frac{1.5}{2.0}$ times that of a solution that does not cause osmotic volume changes of said cell, tissue or organ.

8. (Currently amended) A method for the introduction and washout of vitrifiable concentrations of cryoprotectants in a cell, tissue or organ, comprising:

adding the solution of Claim 2 1 or Claim 11 to said cell, tissue or organ; and removing the solution from the cell, tissue or organ.

9. (Currently Amended) A method for the cryopreservation of living systems by vitrification comprising:

adding a solution comprising bicarbonate, mannitol, lactose, and vitrifiable concentrations of cryoprotectant to said living system; and

cooling said living system to a desired temperature.

- 10. (Currently amended) The solution of Claim 1, further comprising 90 mM glucose.
- 11-12. (Cancelled)
- 13. (Currently amended) The solution of Claim 11, 10 further comprising 90 mM glucose, 45 mM mannitol, 45 mM lactose, 7.2 mM potassium phosphate, 1 mM calcium chloride, 2 mM magnesium chloride, 5 mM reduced glutathione, 28.2 mM potassium chloride, 10 mM sodium bicarbonate, and 1 mM adenine HCl.

3

14. (Cancelled)

- 15. (Currently amended) The solution of Claim 14 10, wherein said solution has a tonicity of between 1.1 to 2.0 times that of a solution that does not cause osmotic volume changes of said cell, tissue or organ.
- 16. (Currently amended) The solution of Claim 14 2 wherein said cryoprotectant comprises dimethyl sulfoxide, formamide, and ethylene glycol.
- 17. (Currently amended) The solution of Claim 14 2 wherein said cryoprotectant comprises polyvinyl alcohol or a copolymer of vinyl alcohol and vinyl acetate
- 18. (Currently amended) The solution of Claim 14 2 wherein said cryoprotectant comprises polyglycerol.
- 19. (Currently amended) A solution for the introduction and washout of vitrifiable concentrations of cryoprotectants in a cell, tissue or organ, comprising bicarbonate, mannitol, lactose, and one or more cryoprotectants in an amount sufficient for vitrification of an organ.
- 20. (Currently amended) A solution for the introduction and washout of vitrifiable concentrations of cryoprotectants in a cell, tissue or organ, comprising bicarbonate, mannitol, lactose, and polyvinyl alcohol or a copolymer of vinyl alcohol and vinyl acetate.
- 21. (Previously presented) A solution for the cryopreservation of living systems by vitrification comprising mannitol, lactose, and vitrifiable concentrations of cryoprotectant, wherein said cryoprotectant comprises polyglycerol.

4

- 22. (Previously presented) The solution of Claim 1, wherein said solution has a tonicity of between 1.1 to 2.0 times that of a solution that does not cause osmotic volume changes of said cell, tissue or organ.
- 23. (Previously presented) The solution of Claim 11 10, wherein said solution has a tonicity of between 1.1 to 2.0 times that of a solution that does not cause osmotic volume changes of said cell, tissue or organ.
- 24. (New) The solution of claim 1 wherein the lactose and mannitol are present in equal concentrations.
- 25. (New) The solution of claim 24 wherein the lactose and mannitol are each present at 45 mM.
 - 26. (New) The solution of claim 10 further comprising 10 mM bicarbonate.
- 27. (New) The solution of claim 10, further comprising 22.305% w/v DMSO, 12.858% w/v formamide, 23.837% w/v ethylene glycol, and 1% w/v X1000, 4% w/v decaglycerol in LM5 carrier.
- 28. (New) The solution of claim 10, further comprising 22.305% w/v DMSO, 12.858% w/v formamide, 16.837% w/v ethylene glycol, and 1% w/v X1000, 4% w/v decaglycerol, and 7% w/v acetol in LM5 carrier.
- 29. (New) The solution of claim 10, further comprising 22.305% w/v DMSO, 12.858% w/v formamide, 16.837% w/v ethylene glycol, 1% w/v X1000, 1% w/v decaglycerol, and 7% w/v polyvinylpyrrolidone 5,000 in LM5 carrier.

5

- 30. (New) The solution of claim 7 having a tonicity of 1.2 to 1.5 times that of a solution that does not cause osmotic volume changes of said cell, tissue or organ.
- 31. (New) The solution of Claim 10 wherein the mannitol is present at 45 mM and the lactose is present at 45 mM, and further comprising 7.2 mM potassium phosphate, 5 mM reduced glutathione, 28.2 mM potassium chloride, 10 mM sodium bicarbonate, and 1 mM adenine.
 - 32. (New) The solution of claim 31 further comprising 1 mM CaCl₂ and 2 mM MgCl₂.